EHA 2023 | Cardiotoxicity of CPX-351 vs 7+3 chemotherapy in patients with untreated high-risk AML
Jorge Cortes, MD, Augusta University, Augusta, GA, comments on the results of a subanalysis from a pivotal Phase III study comparing the impact of CPX-351 vs 7+3 chemotherapy on cardiac impairment in a subset of patients with newly diagnosed or secondary acute myeloid leukemia (sAML; NCT01696084). The study reported that CPX-351 is associated with less cardiotoxicity than 7+3, which could be due to either the lower mean cumulative doses of daunorubicin with CPX-351, or the liposomal formulation of CPX-351. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant for Pfizer, Novartis, Takeda, Sun Pharma, Rigel and Forma Therapeutics. Dr Cortes’ institution receives research support from Pfizer, Takeda, Novartis and Sun Pharma.
